首页> 外文期刊>Biochemistry and Biophysics Reports >Accurate clinical genetic testing for autoinflammatory diseases using the next-generation sequencing platform MiSeq
【24h】

Accurate clinical genetic testing for autoinflammatory diseases using the next-generation sequencing platform MiSeq

机译:使用下一代测序平台MiSeq对自身炎症进行准确的临床基因测试

获取原文
       

摘要

Autoinflammatory diseases occupy one of a group of primary immunodeficiency diseases that are generally thought to be caused by mutation of genes responsible for innate immunity, rather than by acquired immunity. Mutations related to?autoinflammatory diseases occur in 12 genes. For example, low-level somatic mosaic NLRP3 mutations underlie chronic infantile neurologic, cutaneous, articular syndrome (CINCA), also known as neonatal-onset multisystem inflammatory disease (NOMID). In current clinical practice, clinical genetic testing plays an important role in providing patients with quick, definite diagnoses. To increase the availability of such testing, low-cost high-throughput gene-analysis systems are required, ones that not only have the sensitivity to detect even low-level somatic mosaic mutations, but also can operate simply in a clinical setting. To this end, we developed a simple method that employs two-step tailed PCR and an NGS system, MiSeq platform, to detect mutations in all coding exons of the 12 genes responsible for autoinflammatory diseases. Using this amplicon sequencing system, we amplified a total of 234 amplicons derived from the 12 genes with multiplex PCR. This was done simultaneously and in one test tube. Each sample was distinguished by an index sequence of second PCR primers following PCR amplification. With our procedure and tips for reducing PCR amplification bias, we were able to analyze 12 genes from 25 clinical samples in one MiSeq run. Moreover, with the certified primers designed by our short program—which detects and avoids common SNPs in gene-specific PCR primers—we used this system for routine genetic testing. Our optimized procedure uses a simple protocol, which can easily be followed by virtually any office medical staff. Because of the small PCR amplification bias, we can analyze simultaneously several clinical DNA samples with low cost and can obtain sufficient read numbers to detect a low level of somatic mosaic mutations. Highlights ? Our MiSeq approach using multiplex PCR has high sensitivity and accuracy. ? It detects even low-level somatic mosaic mutations causing autoinflammatory diseases. ? It is time- and cost-effective and can be performed by average-skilled technicians. ? It minimizes human error, guaranteeing the accuracy needed for diagnostic application.
机译:自身炎症性疾病占据了一组原发性免疫缺陷疾病中的一种,通常被认为是由与先天免疫有关的基因突变引起的,而不是由获得性免疫引起的。与自身炎性疾病相关的突变发生在12个基因中。例如,低水平的体细胞镶嵌NLRP3突变是慢性婴儿神经系统,皮肤,关节综合征(CINCA)的基础,也被称为新生儿多发性炎症(NOMID)。在当前的临床实践中,临床基因检测在为患者提供快速,明确的诊断方面起着重要作用。为了增加此类测试的可用性,需要低成本的高通量基因分析系统,该系统不仅具有检测低水平的体细胞镶嵌突变的灵敏度,而且还可以在临床环境中简单地运行。为此,我们开发了一种简单的方法,该方法采用两步拖尾PCR和NGS系统MiSeq平台来检测导致自身炎性疾病的12个基因的所有编码外显子中的突变。使用该扩增子测序系统,我们通过多重PCR扩增了来自12个基因的总共234个扩增子。同时在一个试管中进行。在PCR扩增之后,通过第二PCR引物的索引序列来区分每个样品。利用我们的程序和减少PCR扩增偏差的技巧,我们能够在一次MiSeq运行中分析25个临床样品中的12个基因。此外,通过我们短程序设计的经过认证的引物(可检测并避免基因特异性PCR引物中的常见SNP),我们将该系统用于常规的基因检测。我们优化的程序使用简单的协议,几乎所有办公室医务人员都可以轻松遵循。由于较小的PCR扩增偏差,我们可以低成本同时分析多个临床DNA样本,并可以获得足够的读数以检测低水平的体细胞镶嵌突变。强调 ?我们使用多重PCR的MiSeq方法具有很高的灵敏度和准确性。 ?它甚至可以检测到导致自身炎症性疾病的低水平体细胞镶嵌突变。 ?它既省时又具有成本效益,可以由普通技术人员执行。 ?它最大程度地减少了人为错误,从而保证了诊断应用所需的准确性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号